Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression

Autor: Da Zhou, Yuan-Wen Chen, Ze-Hua Zhao, Rui-Xu Yang, Feng-Zhi Xin, Xiao-Lin Liu, Qin Pan, Huiping Zhou, Jian-Gao Fan
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Zdroj: Experimental and Molecular Medicine, Vol 50, Iss 12, Pp 1-12 (2018)
Druh dokumentu: article
ISSN: 1226-3613
2092-6413
DOI: 10.1038/s12276-018-0183-1
Popis: Fatty liver disease: A gutsy way to prevent disease progression A treatment for non-alcoholic fatty liver disease that incorporates a metabolite found in the gut could prevent progression to a more serious liver condition. Drugs that enhance the activity of glucagon-like peptide-1 (GLP-1), a protein involved in regulating metabolic processes, have shown promise in targeting non-alcoholic fatty liver disease and the more serious condition, steatohepatitis. However, some patients appear resistant to treatment. Jian-Gao Fan at Shanghai Jiao Tong University in China, Huiping Zhou at McGuire VA Medical Center in Richmond, USA, and co-workers demonstrated that a gut metabolite called sodium butyrate may help encourage responsiveness to GLP-1 treatment. The team found that liver GLP-1R expression was considerably reduced in patients with liver disease compared with healthy controls. Experiments on mouse models showed that treatment incorporating sodium butyrate improved GLP-1R levels and reduced fatty liver deposits.
Databáze: Directory of Open Access Journals
Externí odkaz: